Technical Analysis for BYSI - BeyondSpring, Inc.

Grade Last Price % Change Price Change
grade F 14.51 0.21% 0.03
BYSI closed up 0.21 percent on Friday, May 24, 2019, on 59 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BYSI trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Inside Day Range Contraction 0.00%
50 DMA Resistance Bearish 0.21%
Fell Below 20 DMA Bearish 0.21%
Fell Below 50 DMA Bearish -4.48%
180 Bearish Setup Bearish Swing Setup -4.48%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.48%
Upper Bollinger Band Walk Strength -4.48%
Inside Day Range Contraction -4.48%
Upper Bollinger Band Touch Strength -4.48%

Older signals for BYSI ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Chemistry Biopharmaceutical Cancer Clinical Medicine Chemotherapy Cancer Treatments Organic Chemistry Antineoplastic Drugs Cancer Therapies Docetaxel Advanced Non Small Cell Lung Cancer Buparlisib Imidazoles Neutropenia
Is BYSI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 30.98
52 Week Low 13.06
Average Volume 16,553
200-Day Moving Average 19.6635
50-Day Moving Average 15.7263
20-Day Moving Average 14.844
10-Day Moving Average 15.129
Average True Range 1.1726
ADX 21.33
+DI 18.0244
-DI 12.6096
Chandelier Exit (Long, 3 ATRs ) 13.4555
Chandelier Exit (Short, 3 ATRs ) 16.5778
Upper Bollinger Band 16.1013
Lower Bollinger Band 13.5867
Percent B (%b) 0.37
BandWidth 16.940178
MACD Line -0.1383
MACD Signal Line -0.2025
MACD Histogram 0.0643
Fundamentals Value
Market Cap 331.47 Million
Num Shares 22.8 Million
EPS -3.71
Price-to-Earnings (P/E) Ratio -3.91
Price-to-Sales 0.00
Price-to-Book 16.76
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.88
Resistance 3 (R3) 16.02 15.70 15.65
Resistance 2 (R2) 15.70 15.36 15.63 15.57
Resistance 1 (R1) 15.11 15.14 14.95 14.97 15.50
Pivot Point 14.79 14.79 14.72 14.72 14.79
Support 1 (S1) 14.20 14.45 14.04 14.06 13.52
Support 2 (S2) 13.88 14.23 13.81 13.45
Support 3 (S3) 13.29 13.88 13.37
Support 4 (S4) 13.15